GSK has committed $50 million in upfront capital and near-term milestones to secure a license to two cancer research foundation models from Noetik. San Francisco-based Noetik has used spatial biology ...
SAN FRANCISCO--(BUSINESS WIRE)--Noetik, an AI-native biotech company pioneering self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therapeutics, ...
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Drugmaker GSK and U.S. biotechnology company AnaptysBio started litigation against one another, with each saying the other party breached a licensing agreement for cancer treatment Jemperli. Tesaro, a ...
Some four years into Jemperli’s commercial life span, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio. Tesaro has filed a lawsuit ...
· These critical projects aim to enhance understanding and advance solutions to the urgent public health threat of AMR and drug-resistant infections GSK and the Fleming Initiative today announced six ...
GSK plc (NYSE:GSK) is a major global healthcare company with operations in multiple therapeutic fields, including vaccines, respiratory, and oncology. On October 27, Jefferies in itiated ...
LONDON, Oct 29 (Reuters) - GSK (GSK.L), opens new tab raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit growth, lifting the British ...
GSK Plc raised its profit and sales forecasts for the year, aided by its HIV and immunology medicines, in Emma Walmsley’s last report as chief executive officer. The British drugmaker expects earnings ...
GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. But that dream appeared to die this morning as the pharma closed the last programs related to this ...
Now it's GSK plc's turn (GSK) (GLAXF). Since the publication of my article "GSK's Strong Performance: Why I'm Upgrading to 'Strong Buy'" on February 18, GSK's stock price has risen 20.3%. The reasons ...
GSK has successfully appealed a ruling by the U.K. marketing watchdog that determined a trio of its COVID-19 vaccine press releases had brought discredit on the pharma industry. The case is the latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results